EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience

Jiwon Koh, Jinyong Kim, Go-Un Woo, Hanbaek Yi, So Yean Kwon, Jeongmin Seo, Jeong Mo Bae, Jung Ho Kim, Jae Kyung Won, Han Suk Ryu, Yoon Kyung Jeon, Dae-Won Lee und 13 weitere

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Jiwon Koh und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, High-Throughput Nucleotide Sequencing, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Considering the high disease burden and unique features of Asian patients with breast cancer (BC), it is essential to have a comprehensive view of genetic characteristics in this population. An institutional targeted sequencing platform was developed through the Korea Research-Driven Hospitals project and was incorporated into clinical practice. This study explores the use of targeted next-generation sequencing (NGS) and its outcomes in patients with advanced/metastatic BC in the real world.Materials and Methods We reviewed the results of NGS tests administered to BC patients using a customized sequencing platform—FiRST Cancer Panel (FCP)—over 7 years. We systematically described clinical translation of FCP for precise diagnostics, personalized therapeutic strategies, and unraveling disease pathogenesis.

Results

NGS tests were conducted on 548 samples from 522 patients with BC. Ninety-seven point six percentage of tested samples harbored at least one pathogenic alteration. The common alterations included mutations in TP53 (56.2%), PIK3CA (31.2%), GATA3 (13.8%), BRCA2 (10.2%), and amplifications of CCND1 (10.8%), FGF19 (10.0%), and ERBB2 (9.5%). NGS analysis of ERBB2 amplification correlated well with human epidermal growth factor receptor 2 immunohistochemistry and in situ hybridization. RNA panel analyses found potentially actionable and prognostic fusion genes. FCP effectively screened for potentially germline pathogenic/likely pathogenic mutation. Ten point three percent of BC patients received matched therapy guided by NGS, resulting in a significant overall survival advantage (p=0.022), especially for metastatic BCs.

Conclusion

Clinical NGS provided multifaceted benefits, deepening our understanding of the disease, improving diagnostic precision, and paving the way for targeted therapies. The concrete advantages of FCP highlight the importance of multi-gene testing for BC, especially for metastatic conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHigh-Throughput Nucleotide SequencingBiomarkers, TumorHumansFemaleMiddle AgedMutationAdultAgedPrecision MedicinePrognosisRepublic of KoreaAged, 80 and over

Stichwörter der Autor:innen

Breast neoplasmsCancer evolutionCopy number variationFusion geneHereditary cancerMutationNext-generation sequencing

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Cancer Research Institute, Seoul National University, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Genomic Medicine, Seoul National University Hospital, Seoul, Korea.
  • Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.

Förderung

  • Ministry of Health and Welfare

Zitieren

APA

Koh, J., Kim, J., Woo, G. U., Yi, H., Kwon, S. Y., Seo, J., Bae, J. M., Kim, J. H., Won, J. K., Ryu, H. S., Jeon, Y. K., Lee, D. W., Kim, M., Kim, T. Y., Lee, K. H., Kim, T. Y., Lee, J. S., Seong, M. W., Kim, S., …, & Im, S. A. (2025). Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.296

Vancouver

Koh J, Kim J, Woo GU, Yi H, Kwon SY, Seo J, et al. Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.296

BibTeX
@article{Koh2025,
  author = {Koh, Jiwon and Kim, Jinyong and Woo, Go-Un and Yi, Hanbaek and Kwon, So Yean and Seo, Jeongmin and Bae, Jeong Mo and Kim, Jung Ho and Won, Jae Kyung and Ryu, Han Suk and Jeon, Yoon Kyung and Lee, Dae-Won and Kim, Miso and Kim, Tae-Yong and Lee, Kyung-Hun and Kim, Tae-You and Lee, Jee-Soo and Seong, Moon-Woo and Kim, Sheehyun and Lee, Sungyoung and Yun, Hongseok and Song, Myung Geun and Choi, Jaeyong and Kim, Jong-Il and Im, Seock-Ah},
  title = {Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.296}
}
Kostenlos starten →